Neuroplastin modulates anti-inflammatory effects of MANF

Takuya Yagi  
*Washington University School of Medicine in St. Louis*

Rie Asada  
*Washington University School of Medicine in St. Louis*

Kohsuke Kanekura  
*Tokyo Medical University*

Ave Eesmaa  
*University of Helsinki*

Maria Lindahl  
*University of Helsinki*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Please let us know how this document benefits you.**

**Recommended Citation**

Yagi, Takuya; Asada, Rie; Kanekura, Kohsuke; Eesmaa, Ave; Lindahl, Maria; Saarma, Mart; and Urano, Fumihiko, "Neuroplastin modulates anti-inflammatory effects of MANF." *iScience*. 23, 12. 101810 (2020).  
[https://digitalcommons.wustl.edu/open_access_pubs/10049](https://digitalcommons.wustl.edu/open_access_pubs/10049)
Neuroplastin Modulates Anti-inflammatory Effects of MANF

HIGHLIGHTS
Neuroplastin (NPTN) is a plasma membrane receptor for MANF
NPTN regulates MANF-mediated suppression of inflammation
NPTN regulates cell survival mediated by MANF under ER stress
MANF-NPTN survival pathway provides potential therapeutic targets for ER stress-related disorders
Neuroplastin Modulates Anti-inflammatory Effects of MANF

Takuya Yagi,1,5 Rie Asada,1,5 Kohsuke Kanekura,3 Ave Eesmaa,4 Maria Lindahl,4 Mart Saarma,4 and Fumihiko Urano1,2,6,*

SUMMARY
Endoplasmic reticulum (ER) stress is known to induce pro-inflammatory response and ultimately leads to cell death. Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an ER-localized protein whose expression and secretion is induced by ER stress and a crucial survival factor. However, the underlying mechanism of how MANF exerts its cytoprotective activity remains unclear due to the lack of knowledge of its receptor. Here we show that Neuroplastin (NPTN) is such a receptor for MANF. Biochemical analysis shows the physiological interaction between MANF and NPTN on the cell surface. Binding of MANF to NPTN mitigates the inflammatory response and apoptosis via suppression of NF-κB signaling. Our results demonstrate that NPTN is a cell surface receptor for MANF, which modulates inflammatory responses and cell death, and that the MANF-NPTN survival signaling described here provides potential therapeutic targets for the treatment of ER stress-related disorders, including diabetes mellitus, neurodegeneration, retinal degeneration, and Wolfram syndrome.

INTRODUCTION
The endoplasmic reticulum (ER) participates in many important cellular processes. This includes the native folding, post-translational modification, and trafficking of transmembrane and secretory proteins. Genetic or acquired dysfunction of the ER leads to a variety of diseases. Imbalance between the demand for secretory and membrane proteins and the protein folding capacity of ER results in a buildup of unfolded/misfolded proteins in the ER. The status in which unfolded/misfolded proteins are accumulated in the ER lumen is referred to as ER stress. Once ER stress occurs, it is mitigated by a signaling mechanism known as the unfolded protein response (UPR) (Ron and Walter, 2007; Schroder and Kaufman, 2005). The UPR maintains ER homeostasis through three distinct physiological responses: (1) translational attenuation to decrease the demands made on the organelle (Harding et al., 2002), (2) the transcriptional induction of genes encoding ER-resident chaperones to facilitate protein folding (Li et al., 2000; Yoshida et al., 1998), and (3) ER-associated degradation (ERAD) to degrade unfolded or misfolded proteins in the ER lumen (Ng et al., 2000; Travers et al., 2000). Excessive and unresolved ER stress induces pro-inflammatory response and eventually leads to apoptotic cell death, which contributes to the pathogenesis of a variety of diseases including neurodegenerative disorders and diabetes mellitus (Nakagawa et al., 2000; Urano et al., 2000).

MANF is an ER stress responsive protein whose expression and secretion are enhanced by ER stress (Apostolou et al., 2008; Mizobuchi et al., 2007). MANF together with cerebral dopamine neurotrophic factor (CDNF) was originally identified as highly evolutionarily conserved neurotrophic factors (NTFs) forming a novel family of NTFs (Lindahl et al., 2017; Lindholm and Saarma, 2010; Lindholm et al., 2007; Petrova et al., 2003). Traditionally, it was considered that there were three families of NTFs: (1) neurotrophin family, (2) glial cell line-derived neurotrophic factor (GDNF) family of ligands (GFLs), and (3) neurotrophic cytokines (neurokines). By binding to and activating their receptors on the cell surface, NTFs transmit cytoprotective and survival signals via a phosphorylation cascade (Airaksinen et al., 1999; Chao, 2003). MANF and CDNF are structurally distinct from all other families of NTFs and signal through unknown receptors or mechanisms (Lindahl et al., 2017).

Previous studies demonstrated that MANF is a protective factor for dopamine neurons in animal models of Parkinson disease, cardiac myocytes in myocardial infarction, cortical neurons in ischemic stroke, and...
Figure 1. Identification of MANF Receptor by a Ligand Receptor Capture (LRC) Technology

(A) Fluorescence-activated cell sorting (FACS) analysis examining the binding and cross-linking of MANF peptide-TRICEPS and Insulin peptide-TRICEPS to the oxidized glycans on the cell surface of INS-1 832/13 cells.

(B) CaptiRec volcano plot to compare enriched proteins analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in the Insulin and MANF peptide samples. Data are shown on the protein level.

(C) Immunoblot analysis monitoring NPTN and MANF-TRICEPS in HeLa cells treated with mock (-) or MANF-TRICEPS (+).

(D) The evaluation of NPTN knockdown with lentivirus expressing shGFP or shNPTN in HeLa cells. Left panel is a representative immunoblot image of NPTN and GAPDH. GAPDH was used as a loading control. Right graph is quantitative analysis of NPTN from three independent experiments (n = 3; values are mean ± SD, **p < 0.001, unpaired two-tailed Student’s t test).
As NTFs are known to bind to cell surface receptors to activate downstream signaling, a specific receptor for MANF is expected to exist. In this study, we show that neuroplastin (NPTN) is such a cell surface receptor for MANF. NPTN mediates the expression and secretion of inflammatory cytokines through activation of the NF-κB pathway, and MANF antagonizes the inflammatory effect of NPTN by direct physical interaction, resulting in the suppression of ER stress-mediated inflammation and cell death. Our study reveals a mechanism of MANF-mediated cell survival and anti-inflammation.

RESULTS

An Unbiased Cell Surface Binding Assay to Identify MANF Receptor Candidates

To identify cell surface molecules that bind to the extracellular MANF in mammalian cells, we adapted a ligand-receptor capture system TRICEPS (Frei et al., 2012). This system utilizes a specifically designed chemoproteomic reagent TRICEPS, which has three heads: one is covalently coupled to a ligand of interest, one is used for cross-linking to oxidized glycan of the target receptor, and one is modified with biotin for purification with streptavidin. MANF protects pancreatic β-cells from ER stress-mediated cell death in vitro and in vivo (Lindahl et al., 2014). Therefore, we hypothesized that pancreatic β-cells might have abundant MANF receptor expression. To test this idea, we used MANF and insulin polypeptides as ligands to capture receptor candidates in a rat β-cell line INS-1 832/13 cells. The receptor capturing efficiency was monitored by flow cytometric analysis of fluorescein isothiocyanate (FITC)-labeled streptavidin. As shown in Figure 1A, the robust fluorescent signal of INS-1 832/13 cells labeled by FITC-streptavidin indicates that MANF-TRICEPS, as well as Insulin-TRICEPS, bound to cell surface molecules efficiently. After purification with streptavidin beads, samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). 882 glycopeptides were identified and quantified in our experiments. Among those, 269 glycopeptides were known to be localized to the cell membrane. As expected, Insulin-TRICEPS captured insulin-like growth factor 1 (IGF1) receptor, one of the known insulin receptors, indicating that this LRC screen worked properly (Varewijck and Janssen, 2012). MANF-TRICEPS sample captured two receptor candidates, neuroplastin (NPTN) and SLC44A3 (also known as CTL3) (Figure 1B). To confirm the binding between MANF and these candidate receptors, we conducted a pull-down assay. The assay revealed that MANF interacted with NPTN, but not with SLC44A3 (Figure 1C). NPTN knockdown by short hairpin RNA (shRNA) in HeLa cells significantly reduced the signal of the cells labeled by FITC-streptavidin (Figures 1D–1F), suggesting that MANF interacts with NPTN in vivo. Because CDNF has a structural similarity with MANF, we tested the ability of CDNF to bind NPTN using microscale thermophoresis. MANF, CDNF, and GDNF (negative control) polypeptides were titrated with varying concentrations of NPTN polypeptide. We found strong binding of NPTN to MANF, but not to CDNF or GDNF, indicating that NPTN is a specific binding partner with MANF. Based on these analyses, we focused on NPTN to verify if NPTN is a receptor for MANF.

NPTN Is Upregulated under ER Stress

First, we sought to determine whether NPTN expression could be increased by ER stress because MANF expression is known to be increased under ER stress conditions (Apostolou et al., 2008; Mizobuchi et al., 2007). Rat glial C6 cells were treated with thapsigargin, a chemical ER stressor. NPTN mRNA and protein and MANF mRNA levels were increased just like as other known ER stress marker genes (BiP and CHOP) (Figures 2A and 2B).
Another ER stressor, tunicamycin, also increased mRNA levels of NPTN and MANF. On the other hand, this increase was not observed by treatment with staurosporin, an agent that induces apoptosis independently of ER stress, suggesting that NPTN is specifically upregulated by ER stress (Figure 2C and 2D).

**NPTN Induces Inflammation via NF-κB Activation**

Previous studies demonstrate that MANF negatively regulates NF-κB, thus reducing inflammation (Chen et al., 2015b; Hakonen et al., 2018). Indeed, when we performed knockdown of Manf in C6 cells using small interfering RNA (siRNA) (Figures S1A and S1B), Manf knockdown cells showed increased NF-κB activation (Figure S1C). Consistent with this finding, mRNA and secretion levels of proinflammatory cytokine, interleukin (IL)-6, and CXCL-1 (ortholog of human IL-8) were increased in Manf knockdown cells (Figures S1D–S1F). Therefore, we tested if NPTN might be involved in inflammation and NF-κB activation. Treatment of C6 cells with lipopolysaccharide (LPS) robustly increased NF-κB-dependent luciferase activity in control, whereas Nptn knockdown suppressed the luciferase activity both in untreated and LPS-treated cells (Figures 3A, S2A, and S2B). In addition, Nptn knockdown significantly reduced mRNA and secretion levels of IL-6 (Figures 3B and 3C). We next conducted overexpression of Nptn using Np55-EGFP (a shorter isoform of NPTN) or Np65-EGFP (a longer isoform of NPTN) vector (Figure S1C). Contrary to knockdown experiments, transient overexpression of Np55 and Np65 significantly induced NF-κB-dependent luciferase activity, as well as mRNA and secretion levels of IL-6 (Figures 3D–3F). Collectively, these results indicate that NPTN activates inflammatory responses through NF-κB signaling.
MANF Suppresses NF-κB Activation through NPTN

Given the direct binding between MANF and NPTN, we tested if MANF might suppress the NF-κB activity through NPTN. First, we investigated the dynamics of this interaction in the presence of ER stress or inflammatory stimuli. After co-transfecting Np65-EGFP and MANF expression vectors in HeLa cells, we treated these cells with or without thapsigargin or LPS. The cell lysates were immunoprecipitated with anti-GFP antibody and subsequently immunoblotted. The amount of MANF interacting with NPTN was not changed by the treatment with either thapsigargin or LPS, indicating that ER stress and inflammatory stimuli do not affect the interaction between NPTN and MANF (Figure S3). Consistent with previous reports and our observations (Figure S1), co-treatment with recombinant MANF polypeptide and LPS reduced NF-κB-dependent luciferase activity compared with LPS alone. This reduction was blunted in Nptn knockdown cells (Figure 4A). Under basal conditions, NF-κB complexes with IκB, which is a physiological inhibitor for NF-κB. Under inflammatory conditions, IκB is degraded by the ubiquitin-proteasome system. This is followed by the release of active NF-κB, which promotes transcription of inflammatory cytokines (Afonina et al., 2017). LPS stimulation decreased the protein levels of IκB, which was restored by MANF (Figure 4B). Knockdown of Nptn negated the effects of MANF on IκB protein levels. Furthermore, MANF treatment significantly suppressed the expressions of the well-established NF-κB target genes, IL-6 and Cxcl-1 (IL-8). Knockdown of Nptn attenuated this effect (Figures 4C and 4D). As reported previously, ER stress induces inflammation leading to cell death (Hotamisligil, 2010). Thapsigargin treatment increased not only mRNA expression levels of IL-6 and Cxcl-1 (IL-8) but also those of Chop, which is a major molecule in ER stress-induced cell death (Figure 4D). Additionally, caspase 3/7 activity was increased by thapsigargin treatment.
**DISCUSSION**

MANF was originally identified as the new family member of NTFs. Further studies revealed that MANF is highly expressed in non-neuronal tissues and circulates in the blood (Lindahl et al., 2017). MANF signaling is an emerging therapeutic target in neurodegenerative diseases, diabetes mellitus, stroke, retinal damage, and Wolfram syndrome, a genetic disorder characterized by diabetes and retinal and neuronal degeneration. However, the plasma membrane receptor for MANF involved in cytoprotective and anti-inflammatory effects was not identified. In this study, we show that NPTN is such a receptor for MANF.

Several previous studies demonstrated that MANF inhibits inflammation (Chen et al., 2015a; Liu et al., 2019; Neves et al., 2016). Our study demonstrates that NPTN has pro-inflammatory effects that are suppressed by MANF. Recently, the pro-inflammatory secretory proteins, S100A8 and S100A9, bind to two isoforms of NPTN, Np65 and Np55, respectively (Sakaguchi et al., 2016). S100A9 is also reported to exclusively bind to CD147, which in turn mediates the anti-inflammatory effects of MANF may be mediated by the inhibition of S100A9 and/or TRAF2. 

**Figure 4.** MANF Inhibits NF-κB Pathway via NPTN

(A) Luciferase assay with C6 cells cotransfected with NF-κB luciferase, pRL-TK, and either siCtrl or siNptn. At 48 h after transfection, the cells were pre-treated with or without MANF (3 μg/mL for 1 h) before LPS treatment (100 ng/mL for 8 h) and then the luciferase activity was measured (n = 6; values are mean ± SD, *p < 0.05). (B) Representative immunoblot images of IκBα and GAPDH with C6 cells transfected with siCtrl or siNptn. At 48 h after transfection, the cells were pre-treated with MANF (3 μg/mL for 1 h) before LPS treatment (100 ng/mL for 8 h) (n = 3; values are mean ± SD, *p < 0.05). (C) qPCR analysis of Il-6 and Cxcl-1 (Il-8) using C6 cells transfected with siCtrl or siNptn. At 48 h after transfection, the cells were pre-treated with or without MANF (3 μg/mL for 1 h) before LPS treatment (100 ng/mL for 8 h) (n = 3; values are mean ± SD, *p < 0.05). (D) qPCR analysis of Il-6, Cxcl-1 (Il-8), and Chop using C6 cells transfected with siCtrl or siNptn. After 48 h of transfection, the cells were pre-treated with or without MANF (3 μg/mL for 1 h) before TG treatment (100 nM for 8 h) (n = 3; values are mean ± SD, *p < 0.05). (E) C6 cells were treated with TG (100 nM, for 8 h) 48 h after transfection with siCtrl or siNptn. Caspase 3/7 activity was monitored by a Promega Caspase-Glo 3/7 kit (n = 6; values are mean ± SD, *p < 0.05). (F) qPCR analysis of Il-6 using C6 cells transfected with siCtrl, siManf, or siManf and siNptn. At 48 h after transfection, the cells were treated with or without TG (100 nM, for 8 h) (n = 3; values are mean ± SD, *p < 0.05). (G) qPCR analysis of Il-6 in primary cultured MEF from wild-type (WT) or Nptn knockout (KO) mice. The cells were pre-treated with or without MANF (3 μg/mL for 1 h) before LPS treatment (100 ng/mL for 8 h) (n = 3; values are mean ± SD, *p < 0.05). (H) qPCR analysis of Il-6 with INS-1E cells. The cells were treated with cytokine cocktail (IL-1β and IFN-γ 50 ng/mL for 8 h) 48 h after transfection with siCtrl or siNptn (n = 3; values are mean ± SD, *p < 0.05). (I) INS-1E cells were treated with cytokine cocktail (IL-1β and IFN-γ 50 ng/mL for 8 h) 48 h after transfection with siCtrl or siNptn, then caspase 3/7 activity was monitored by a Promega Caspase-Glo 3/7 kit (n = 6; values are mean ± SD, *p < 0.05). (J) Schematic of the relationship between NPTN and MANF. Statistical analysis of data was performed by one-way ANOVA followed by Dunnett’s test.
ER stress-mediated inflammation is a promising target for preventing β-cell death in diabetes (Clark and Urano, 2016; Lerner et al., 2012; Olsowski et al., 2012; Papa, 2012). MANF-deficient mice develop diabetes due to ER stress-mediated pancreatic β-cell death (Lindahl et al., 2014). Furthermore, increased circulating MANF levels have been detected in the sera of patients with type 1 and type 2 diabetes (Galli et al., 2016; Wu et al., 2017). Our data demonstrate that MANF mitigates inflammation and cell death by suppressing the NPTN-mediated inflammatory signal in a cell model of type 1 diabetes. In addition to diabetes mellitus, cytoprotective effects of MANF have also been shown in animal models of Parkinson disease, ischemia, and retinal neurodegenerative diseases (Airavaara et al., 2009; Glembotski et al., 2012; Lu et al., 2018; Neves et al., 2016; Voutilainen et al., 2009). Furthermore, we have recently reported that MANF prevents ER stress-mediated β-cell death in cell and mouse models of Wolfram syndrome (Mahadevan et al., 2020). These previous reports and our findings indicate that screening assays, such as surface plasmon resonance (SPR), to discover small molecules that bind to NPTN and mediate survival and anti-inflammatory effects will lead to a novel therapeutic strategy for a variety of ER stress-related diseases, including diabetes, neurodegeneration, retinal degeneration, and Wolfram syndrome (Abreu and Urano, 2019).

Ca2+ homeostasis is known to play a pivotal role in fine-tuning insulin release from pancreatic β-cells. ER dysfunction, in particular ER stress, leads to disruptions in Ca2+ homeostasis that interfere with β-cell function (Clark and Urano, 2016; Marre and Piganelli, 2017). The key molecules linking ER homeostasis and Ca2+ signaling are not clear. Our study has revealed that ER stress responsive protein MANF physically interacts with NPTN. Recent reports demonstrated that NPTN regulates intracellular Ca2+ homeostasis by stabilizing plasma membrane Ca2+-ATPases (PMCA) (Korthals et al., 2017; Schmidt et al., 2017). CD147 has been shown to be an essential subunit of the PMCA complex and a key regulator of Ca2+ clearance (Schmidt et al., 2017). In addition, MANF has been reported to revert phosphorylation of ryanodine receptor 2 (RyR2) leading the inhibition of Ca2+ leakage from the ER (Park et al., 2019). Although downstream of the interaction between MANF and NPTN remains unclear, both these molecules may contribute to the regulation of β-cell function, especially maintaining Ca2+ homeostasis.

Here, we report the discovery of NPTN as a plasma membrane receptor for MANF. Our findings indicate that NPTN is involved in the intercellular regulation of inflammation and cell survival mediated by MANF (Figure 4J). It has been shown that MANF interacts with BiP in the ER and regulates protein-folding homeostasis (Yan et al., 2019). Because MANF is also located in the lumen of the ER, it is possible that there are other binding partners for MANF exerting its survival and anti-inflammatory effects. Nevertheless, our study paves the way to develop MANF-based therapies for human disorders, including β cell death in type 1 and type 2 diabetes, neurodegenerative diseases, and Wolfram syndrome characterized by juvenile onset-diabetes, optic nerve atrophy, and neurodegeneration.

Limitations of the Study
In this article, we show that NPTN is a plasma membrane receptor for MANF and regulates intercellular regulation of inflammation and cell survival mediated by MANF under ER stress conditions. Although steady-state interaction between MANF and NPNT is shown in Figures 1C and 1G, the dynamics of this interaction in the presence of ER stress inducers and inflammatory stimuli are still not clear and should be investigated further (Figure S3).

Resource Availability
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Fumihiko Urano (urano@wustl.edu).

Materials Availability
All cell lines and reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Data and Code Availability
All data are included in the published article and the Supplemental Information, and any additional information will be available from the lead contact upon request.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101810.

ACKNOWLEDGMENTS

This work was partly supported by the grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) (DK112921), the National Center for Advancing Translational Sciences (NCATS) of the NIH (TR002065), and philanthropic supports from the Unravel Wolfram Syndrome Fund, the Silberman Fund, the Stowe Fund, the Snow Foundation, the Eye Hope Foundation, the Ellie White Foundation for the Rare Genetic Disorders, and the Feigek Fund to F.U. Research reported in this publication was also supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from NCATS of the NIH and Washington University Diabetes Research Center grant P30DK020579 from the NIDDK of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. T.Y. was partly supported by fellowships from the Japan Society for the Promotion of Science, the Uehara Memorial Foundation, and the Kanae Foundation. We thank Dr. Karl-Heinz Smalla (Leibniz Institute for Neurobiology) for providing Np55-EGFP and Np65-EGFP.

AUTHOR CONTRIBUTIONS

F.U. and T.Y. conceived the project. F.U., T.Y. R.A., and M.S. designed the experiments. T.Y., R.A., K.K., A.E., M.L., and M.S. performed and analyzed the experiments. F.U. supervised the work. R.A., T.Y., K.K., A.E., M.L., M.S., and F.U. wrote and edited the manuscript.

DECLARATION OF INTERESTS

F.U. received research funding from Eli Lilly, Ono Pharmaceuticals, and Amaranthus BioScience for the development of MANF-based regenerative therapy for Wolfram syndrome and diabetes previously. F.U. and K.K. are inventors of a patent related to MANF, US 9,891,231 B2 SOLUBLE MANF IN PANCREATIC BETA CELL DISORDERS. M.S. and M.L. are inventors of a patent, Neurotrophic factor MANF and uses thereof (9592279), which is owned by Herantis Pharma.

Received: April 24, 2020
Revised: June 22, 2020
Accepted: November 11, 2020
Published: December 18, 2020

REFERENCES

Abreu, D., and Urano, F. (2019). Current landscape of treatments for Wolfram syndrome. Trends Pharmacol. Sci. 40, 711–714.
Afonina, I.S., Zhong, Z., Karin, M., and Beyaert, R. (2017). Limiting inflammation—The negative regulation of NF-kappaB and the NLRP3 inflammasome. Nat. Immunol. 18, 861–869.
Airaksinen, M.S., Titievsky, A., and Saarma, M. (1999). GDNF family neurotrophic factor signaling: four masters, one servant? Mol. Cell Neurosci. 13, 313–325.
Airavaara, M., Shen, H., Kuo, C.C., Peranen, J., Saarma, M., Hoffer, B., and Wang, Y. (2009). Mesencephalic astrocyte-derived neurotrophic factor reduces ischemic brain injury and promotes behavioral recovery in rats. J. Comp. Neurol. 515, 116–124.
Apostolou, A., Shen, Y., Liang, Y., Luo, J., and Fang, S. (2008). Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp. Cell Res. 314, 2454–2467.
Beesley, P.W., Herrera-Molina, R., Smalla, K.H., and Seidenbecher, C. (2014). The Neuroplastin adhesion molecules: key regulators of neuronal plasticity and synaptic function. J. Neurochem. 131, 266–283.
Chao, M.V. (2003). Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 4, 299–309.
Chen, L., Feng, L., Wang, X., Du, J., Chen, Y., Yang, W., Zhou, C., Cheng, L., Shen, Y., Fang, S., et al. (2015a). Mesencephalic astrocyte-derived neurotrophic factor is involved in inflammation by negatively regulating the NF-kappaB pathway. Sci. Rep. 5, 8133.
Chen, L., Wan, L., Du, J., and Shen, Y. (2015b). Identification of MANF as a protein interacting with RTN1-C. Acta Biochim. Biophys. Sin. (Shanghai) 47, 91–97.
Clark, A.L., and Urano, F. (2016). Endoplasmic reticulum stress in beta cells and autoimmune diabetes. Curr. Opin. Immunol. 43, 60–66.
Frei, A.P., Jeon, O.Y., Kilcher, S., Moest, H., Henning, L.M., Jost, C., Pluckthun, A., Mercer, J., Aebersold, R., Carreira, E.M., et al. (2012). Direct identification of ligand-receptor interactions on living cells and tissues. Nat. Biotechnol. 30, 997–1001.
Galli, E., Harkonen, T., Sainio, M.T., Ustav, M., Toots, U., Utts, A., Yliperttula, M., Lindahl, M., Knip, M., Saarma, M., et al. (2016). Increased circulating concentrations of mesencephalic astrocyte-derived neurotrophic factor in children with type 1 diabetes. Sci. Rep. 6, 29098.
Glembocki, C.C., Thuerauf, D.J., Huang, C., Vebich, J.A., Gottlieb, R.A., and Doroudgar, S. (2012). Mesencephalic astrocyte-derived neurotrophic factor protects the heart from ischemic damage and is selectively secreted upon sarco/endoplasmic reticulum calcium depletion. J. Biol. Chem. 287, 25893–25904.
Hakonen, E., Chandra, V., Fogarty, C.L., Yu, N.Y., Ustinov, J., Katayama, S., Galli, E., Danilova, T., Lindholm, P., Vartiainen, A., et al. (2018). MANF protects human pancreatic beta cells against
stress-induced cell death. Diabetologia 61, 2202–2214.

Harding, H.P., Calfon, M., Urano, F., Novoa, I., and Ron, D. (2002). Transcriptional and translation control in the Mammalian unfolded protein response. Annu. Rev. Cell Dev. Biol. 18, 575–599.

Hibino, T., Sakaguchi, M., Miyamoto, S., Yamamoto, M., Motoyama, A., Hosoi, J., Shimokata, T., Ito, T., Tsuibo, R., and Huh, N.H. (2013). S100A8 is a novel ligand of EMPRRIN that promotes melanoma metastasis. Cancer Res. 73, 172–183.

Hotamisigil, G.S. (2010). Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900–917.

Korthals, M., Langnaese, K., Smalla, K.H., Kahne, T., Herrema-Molina, P., Handschu, J., Lehmann, A.C., Mamula, D., Naumann, M., Seidenbecher, C., et al. (2017). A complex of Neuroplastin and Plasma Membrane Ca(2+)-ATPase controls T cell activation. Sci. Rep. 7, 8358.

Kutlu, B., Cardozo, A.K., Darville, M.I., Kruhoffer, M., MAGNusson, N., Omtøft, T., and Ezirik, D.L. (2003). Discovery of gene networks regulating cytokine-induced dysfuction and apoptosis in insulin-producing INS-1 cells. Diabetes 52, 2701–2719.

Lerner, A.G., Upton, J.P., Praveen, P.V., Ghosh, R., Nakagawa, Y., Igbaria, A., Shen, S., Nguyen, V., Backes, B.J., Heiman, M., et al. (2012). IRE1α/β induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab. 16, 250–264.

Li, M., Baumeister, P., Roy, B., Phan, T., Foti, D., Luo, S., and Lee, A.S. (2008). ATF6 as a transcription activator of the endoplasmic reticulum stress element: thapsigargin stress-dependent coupling of stress in the ER to activation of JNK and the unfolded protein response via ERSE-II element. Cell Struct. Funct. 32, 41–50.

Lindahl, M., Danilova, T., Palm, E., Lindholm, P., Voiker, V., Hakonen, E., Ustunov, J., Andressoo, J.O., Harvey, B.K., Saarma, M., et al. (2014). MANF is indispensable for the proliferation and survival of pancreatic beta cells. Cell Rep. 7, 366–375.

Lindahl, M., Saarma, M., and Lindholm, P. (2017). Unconventional neurotrophic factors CDNF and MANF structure, physiological functions and therapeutic potential. Neurobiol. Dis. 97, 90–102.

Lindholm, P., and Saarma, M. (2010). Novel CDNF/MANF family of neurotrophic factors. Dev. Neurobiol. 70, 360–371.

Lindholm, P., Voutilainen, M.H., Laurent, J., Peranen, J., Leppanen, V.M., Andressoo, J.O., Lindahl, M., Janhunen, S., Kalkkinen, N., Timmus, T., et al. (2007). Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448, 73–77.

Liu, J., Wu, Z., Han, D., Wei, C., Liang, Y., Jiang, T., Chen, L., Sha, M., Cao, Y., Huang, F., et al. (2019). Mesencephalic astrocyte-derived neurotrophic factor inhibits liver cancer through small ubiquitin-related modifier (SUMO)ylation-Related suppression of NF-kappaB/Snail signaling pathway and epithelial-mesenchymal transition. Hepatology 71, 1262–1278.

Lopes, M., Kutlu, B., Miani, M., Bang-Berthelsen, C.H., Stirling, J., Pociot, F., Goodman, N., Hood, L., Welsh, N., Bontempi, G., et al. (2014). Temporal profiling of cytokine-induced genes in pancreatic beta cells by meta-analysis and network inference. Genomics 103, 264–275.

Lu, J., Luo, L., Huang, D., Liu, X., Xia, X., Wang, Z., Lam, B.L., Yi, J., Wen, R., and Li, Y. (2018). Photoreceptor protection by mesencephalic astrocyte-derived neurotrophic factor (MANF). eNeuro 5, ENEURO.0199-18.2018.

Mahadevan, J., Monkawa, S., Yagi, T., Abreu, D., Lu, S., Kanekura, K., Brown, C.M., and Urano, F. (2020). A soluble endoplasmic reticulum factor as regenerative therapy for Wolfram syndrome. Lab Invest. 100, 1197–1207.

Marre, M.L., and Pigarelli, J.D. (2017). Environmental factors contribute to beta cell endoplasmic reticulum stress and neo-antigen formation in type 1 diabetes. Front. Endocrinol. 8, 262.

Mizobuchi, N., Noseki, J., Kubota, H., Toyokuni, S., Nozaki, J., Naitoh, M., Koizumi, A., and Nagata, K. (2007). ARMET is a soluble ER protein induced by the unfolded protein response via ERSE-II element. Cell Struct. Funct. 32, 41–50.

Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankev, B.A., and Yuan, J. (2000). Caspase-12 mediates endoplasmic reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403, 98–103.

Nevès, J., Zhu, J., Sousa-Victor, P., Konjukhus, M., Riley, R., Chew, S., Yee, J., Hapner, J., and Lamba, D.A. (2016). Immune modulation by MANF promotes tissue repair and regenerative success in the retina. Science 353, 3364.

Ng, D.T., Spear, E.D., and Walter, P. (2000). The unfolded protein response regulates multiple aspects of secretory and membrane protein biogenesis and endoplasmic reticulum endoplasmic quality control. J Cell Biol. 150, 77–88.

Osloowski, C.M., Hara, T., O’Sullivan-Murphy, B., Kanekura, K., Lu, S., Hara, M., Ishigaki, S., Zhu, L.J., Hayashi, E., Hui, S.T., et al. (2012). Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammatory. Cell Metab. 16, 265–273.

Papa, F.R. (2012). Endoplasmic reticulum stress, pancreatic beta-cell degeneration, and diabetes. Cold Spring Harb. Perspect. Med. 3, a007666.

Park, S.J., Kim, Y., Yang, S.M., Henderson, M.J., Way, W., Zimbler, A., Hallermann, S., Kulk, A., Fakler, B., et al. (2017). Neuroplastin and basigin are essential auxiliary subunits of plasma membrane Ca(2+)-ATPases and key regulators of Ca(2+) clearance. Neuron 94, 827–838 e9.

Schroder, M., and Kaufman, R.J. (2005). The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739–799.

Travers, K.J., Patil, C.K., Wodick, L., Lockhart, D.J., Weissman, J.S., and Walter, P. (2000). Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell 101, 249–258.

Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H.P., and Ron, D. (2000). Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664–666.

Varejijk, A.J., and Janssen, J.A. (2012). Insulin and its analogues and their affinities for the IGF1 receptor. Endocr. Relat. Cancer. 19, F63–F75.

Voutilainen, M.H., Back, S., Porti, E., Toppinen, L., Lindgren, L., Lindholm, P., Peranen, J., Saarma, M., and Tuominen, R.K. (2009). Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson’s disease. J. Neurosci. 29, 9651–9659.

Wu, T., Zhang, F., Yang, Q., Zhang, Y., Liu, Q., Jiang, W., Cao, H., Li, D., Xie, S., Tong, N., et al. (2017). Circulating mesencephalic astrocyte-derived neurotrophic factor is increased in newly diagnosed prediabetic and diabetic patients, and is associated with insulin resistance. Endocr. J. 64, 403–410.

Yan, Y., Rato, C., Rohland, L., Preisler, S., and Ron, D. (2019). MANF antagonizes nucleotide exchange by the endoplasmic reticulum chaperone BiP. Nat. Commun. 10, 541.

Yoshida, H., Haze, K., Yanagi, H., Yura, T., and Mori, K. (1998). Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J. Biol. Chem. 273, 33741–33749.

Smith, D.L., Kelly, J., et al. (2003). MANF: a new mesencephalic astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol. Neurosci. 20, 173–188.

Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529.

Sakaguchi, M., Yamamoto, M., Miyai, M., Maeda, T., Hiruma, J., Murata, H., Kinoshita, R., Winarsa Ruma, I.M., Putranto, E.W., Inoue, Y., et al. (2016). Identification of an S100A8 receptor neuroplastin-beta and its heterodimer formation with EMPRRIN. J. Invest. Dermatol. 136, 2240–2250.
Supplemental Information

Neuroplastin Modulates

Anti-inflammatory Effects of MANF

Takuya Yagi, Rie Asada, Kohsuke Kanekura, Ave Eesmaa, Maria Lindahl, Mart Saarma, and Fumihiko Urano
**Figure S1.** Manf knockdown induces NF-κB activation, Related to Figure 3.

(A, B) C6 cells were transiently transfected with scrambled siRNA (siCtrl) or siRNA targeting rat Manf (siManf). Protein and mRNA levels of MANF were measured by immunoblot (A) and qPCR (B). GAPDH was used as a loading control (n=3; values are mean ± S.D., *P < 0.05). (C) Luciferase assay with C6 cells co-transfected with NF-κB luciferase, pRL-TK and either siCtrl or siManf. At 48 h after transfection, the cells were treated with LPS 100 ng/ml for 8 hours, then the luciferase activity was measured (n=6; values are mean ± S.D., *P < 0.05). (D) qPCR analysis of Il-6 and Cxcl-1 (Il-8) using C6 cells transfected with siCtrl or siManf (n=3; values are mean ± S.D., *P < 0.05). (E) ELISA of IL-6 secreted from C6 cells transfected with siCtrl or siManf (n=3; values are mean ± S.D., *P < 0.05). Statistical analysis of data was performed by unpaired two-tailed Student’s t test.
**Figure S2. Nptn knockdown and overexpression in C6 cells, Related to Figure 3.**

(A, B) C6 cells were transiently transfected with scrambled siRNA (siCtrl) or siRNA targeting rat Nptn (siNptn). Protein and mRNA levels of Nptn were measured by immunoblot (A) and qPCR (B). GAPDH was used as a loading control (n=3; values are mean ± S.D., *P < 0.05). (C) C6 cells were transiently transfected with a vector expressing EGFP, Np55-EGFP or Np65-EGFP. Immunoblot analysis reveals the expression of EGFP and EGFP-fused Np55 / Np65 proteins detected by GFP antibody. GAPDH was used for loading control. Statistical analysis of data was performed by unpaired two-tailed Student’s t test.
Figure S3, Related to Figure 4.

Figure S3. Treatment with TG or LPS dose not affect the interaction between MANF and NPTN, Related to Figure 4.
HeLa cells were transiently co-transfected with vectors expressing Np65-EGFP and MANF. NPTN was immunoprecipitated by anti-GFP antibody after treatment with TG (100nM) or LPS (100 ng/ml) for 8 hours, then immunoblot analysis was performed. The blot is a representative image from 3 independent experiments. Note that neither treatment affects the interaction of MANF with NPTN. α-Tubulin was used as a loading control.
Figure S4, Related to Figure 4.

INS-1E cells were transiently transfected with scrambled siRNA (siCtrl) or siRNA targeting rat Nptn (siNptn). Protein were measured by immunoblot. GAPDH was used as a loading control.

**Figure S4. Nptn knockdown in INS-1E cells, Related to Figure 4.**

INS-1E cells were transiently transfected with scrambled siRNA (siCtrl) or siRNA targeting rat Nptn (siNptn). Protein were measured by immunoblot. GAPDH was used as a loading control.
**Transparent Methods**

**Ligand–receptor capture**

TriCEPS™-based ligand-receptor capture (LRC) assay was performed utilizing CaptiRec (Dualsystems Biotech AG) to identify cell surface binding proteins for MANF of INS-1 832/13 cells according to manufacture’s protocol. Briefly, TriCEPS™ was coupled with 300 µg of MANF peptide (Peprotech) or human insulin as a control respectively by incubating for 2 hours at 20 °C. Next, to gently oxidize the cell surface proteins of INS-1 832/13 cells, 1.5 mM NaIO₄ was added to 1 x 10⁹ cell suspension. After incubation at 4 °C in the dark for 15 min, the cells were washed twice and then resuspended in PBS (pH 6.5). For the receptor capture reaction, the oxidized cells were treated with 100 µg of TriCEPS™-MANF / Insulin for 90 min at 4 °C under constant agitation. After collecting an aliquot from each sample for FACS analysis to confirm the receptor capturing efficiency, the cells were collected and the cell pellets were sent to Dualsystems Biotech AG for LC-MS/MS analysis.

The samples were analyzed on a Thermo LTQ Orbitrap XL spectrometer fitted with an electrospray ion source. The samples were measured in data dependent acquisition mode in a 40 min gradient using a 10cm C18. The nine individual samples in TriCEPS™-MANF / Insulin dataset were analyzed with a statistical ANOVA model. This model assumes that the measurement error follows Gaussian distribution and views individual features as replicates of a protein's abundance and explicitly accounts for this redundancy. It tests each protein for differential abundance in all pairwise comparisons of MANF and Insulin samples and reports the p-values. Next, p-values are adjusted for multiple comparisons to control the experiment-wide false discovery rate (FDR). The adjusted p-value obtained for every protein is plotted against the magnitude of the fold enrichment between the two experimental conditions. The area in the
volcano plot that is limited by an enrichment factor of 2 fold or greater and an FDR-adjusted p-value less than or equal to 0.05 is defined as the receptor candidate space.

**Flow cytometric analyses**

After incubating cells with TriCEPS–ligand complexes, cells were washed twice and stained with streptavidin-FITC (BD Biosciences) in FACS buffer (1% FBS in PBS) for 20 min. Labeled cells were washed once and analyzed with LSR II (BD Biosciences). The results were analysed by Flowjo X (10.0.7r2) software.

**Coimmunoprecipitation with TriCEPS–ligand complexes**

After incubating cells with TriCEPS–ligand complexes, cells were lysed in cell lysis buffer (150 mM NaCl, 0.5 % NP40, 50 mM HEPES pH 7.4, 1 mM EDTA and protease inhibitor cocktail (Roche)) followed by centrifugation at 15,000 rpm to remove cellular debris. The supernatants were mixed with Streptavidin (Cell Signaling) and incubated at 4°C for 4 hours. The beads were washed four times with the cell lysis buffer and analyzed by SDS-PAGE and immunoblot analysis.

**Microscale thermophoresis**

Recombinant MANF (P-101-100, Icosagen), CDNF (Biovian) and GDNF (P-103-100, Icosagen) were fluorescently labeled with Alexa647 using the Monolith Protein Labeling Kit RED-NHS following manufacturer’s instructions (MO-L001, Nanotemper Technologies). Labeled proteins were purified from the free dye using Zeba Spin Desalting columns (89882, Thermo Scientific). During all runs, the concentration of labeled molecules was kept constant at 10nM. Recombinant NPTN was titrated over a range of concentrations from 0.122-1000nM. All experiments were done
using the Monolith NT.115 Premium Capillaries (MO-K025) and MST buffer (10mM Na-phosphate buffer, pH7.4, 1mM MgCl$_2$, 3mM KCl, 150mM NaCl and 0.05% Tween-20). MST measurements were done using the Monolith NT.115 instrument with MST power at low setting, excitation power at 100%.

**Transfection and plasmids**

Np55-EGFP and Np65-EGFP were generously gifted from Dr. Karl-Heinz Smalla (Leibniz Institute for Neurobiology). Lentivirus constructs expressing shRNA were obtained from the Genome Institute of Washington University in St. Louis. The shRNA target sequences are as follows: shGFP, CGACGTAAACGGCCACAAGTT; human shNPTN, CATGGAGTACAGGATCAATAA.

**Primary MEFs cultures**

Primary MEFs cultures were obtained from WT or Nptn/- mice embryos at E13.5 or 14.5. Their limbs were collected for genotyping before digestion. The embryos were finely minced after dissecting out the head and visceral tissue. Minced tissue was digested in 0.05% Trypsin / EDTA (ThermoFisher Scientific), and isolated MEFs were grown in the medium described above. MEFs were used for experiments within three passages.

**Quantitative real-time PCR**

Total RNA was isolated from the cells using RNeasy Mini Kit (Qiagen) according to manufacture’s instruction. Purified RNA was reverse transcribed to cDNA using ImProm-II
Reverse Transcription System (Promega). Quantitative real-time PCR used was performed on a ViiA 7 Real-Time PCR System (Applied Biosystems) using PowerUp SYBR Green Master Mix (Applied Biosystems). The relative expression for each gene was measured by the standard curve method and normalized against β-actin expression.

**Luciferase Assay**

pGL4.32[luc2P/NF-kB-RE/Hygro] (Promega) and pRL-TK (Promega) were used for reporter assay. Cells were cotransfected with plasmids/siRNA and reporters as indicated. After 48 hours, the cells were treated with the indicated reagents. Luciferase activity was evaluated by the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer’s protocol. Values obtained from Firefly luciferase signals were normalized to Renilla luciferase activity.

**Measurement of apoptosis**

Cells were plated to 96 well plates and pre-treated with or without MANF peptide at indicated concentrations for 1 hour. After pre-treatment, the cells were treated with the indicated reagents. Caspase 3/7 activity was then detected using the Caspase-Glo® 3/7 Assay (Promega) using the Infinite M1000 plate reader (Tecan).

**Measurement of IL-6**

Cells were plated to 24 well plates and transfected with plasmids/siRNA. After 48 hours, IL-6 produced in culture medium was measured with an IL-6 Rat ELISA Kit (ThermoFisher Scientific) according to the manufacturer’s protocol.
Yagi & Asada et al.

Statistical analysis

Statistical analysis of the data was performed by one-way analysis of variance (ANOVA) followed by Dunnet’s test or Student’s t-test using SPSS 22 (IBM).

Cells

HeLa and C6 cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, ThermoFisher Scientific), supplemented with 10% FBS (ThermoFisher Scientific), penicillin (100 U/ml, ThermoFisher Scientific) and streptomycin (100 µg/ml, ThermoFisher Scientific). MEFs were grown in the same medium additionally containing 1% MEM Non-Essential Amino Acids (NEAA ThermoFisher Scientific). INS-1 832/13 cells were grown in Roswell Park Memorial Institute (RPMI) 1640 Medium (ThermoFisher Scientific), supplemented with 10% FBS, 1mM sodium pyruvate (ThermoFisher Scientific), 100 µM β-mercaptoethanol (SIGMA), penicillin, and streptomycin. INS-1E cells were grown in RPMI 1640 Medium, supplemented with 10% FBS, 10mM HEPES, 1mM sodium pyruvate, 1% NEAA, 50 µM β-mercaptoethanol, penicillin, and streptomycin. All kinds of cells were maintained in a humidified atmosphere containing 5% CO2.

Animals

NPTN deficient mice were obtained from INFRAFRONTIER (Strain name: C57BL/6N-Nptn<tm1a(EUCOMM)Hmgu>/H). Animal experiment was performed according to procedures approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine.
# KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| polyclonal sheep anti-mouse NPTN | R&D Systems | Cat# AF7818, RRID:AB_2715517 |
| monoclonal mouse anti-human NPTN | Novus Biologicals | Cat#NBP1-47374, RRID:AB_10010327 |
| polyclonal rabbit anti-SLC44A3 | GeneTex | Cat# GTX46769, RRID:AB_11172502 |
| polyclonal rabbit anti-MANF | Abnova Corporation | Cat# PAB13301, RRID:AB_10546841 |
| monoclonal rabbit anti-BiP | Cell Signaling | Cat# 3177, RRID:AB_2119845 |
| monoclonal mouse anti-\(\beta\)B | Cell Signaling | Cat# 4814, RRID:AB_390781 |
| monoclonal rabbit anti-GAPDH | Cell Signaling | Cat# 2118, RRID:AB_561053 |
| monoclonal mouse anti-GFP | MBL | Cat# M048-3, RRID:AB_591823 |
| **Chemicals, Peptides, and Recombinant Proteins** | | |
| Tunicamycin | Sigma | Cat# T7765 |
| Thapsigargin | Sigma | Cat# T9033 |
| Staurosporin | Sigma | Cat# S6942 |
| Recombinant Human MANF | Peprotech | Cat# 450-06 |
| Recombinant Rat IL-1 \(\beta\) | R&D Systems | Cat# 501-RL |
| Recombinant Rat IFN-\(\gamma\) | R&D Systems | Cat# 585-IF |
| Streptavidin-HRP | Cell Signaling | Cat# 3999 |
| FITC Streptavidin | BD | Cat# 554060 |
| **Critical Commercial Assays** | | |
| CaptiRec | Dualsystems Biotech AG | Cat# P05201 |
| Caspase-Glo® 3/7 Assay System | Promega | Cat# G8090 |
|                                | Company                | Catalog Number |
|--------------------------------|------------------------|----------------|
| IL-6 Rat ELISA Kit            | Thermo Fisher Scientific | Cat# BMS625    |
| Dual-Luciferase® Reporter Assay System | Promega | Cat# E1910    |
| RNeasy Mini kit               | QIAGEN                 | Cat# 74104     |
| High-Capacity cDNA Reverse Transcription Kit | Thermo Fisher Scientific | Cat# 4368814 |
| Powerup TM SYBR TM Green      | Thermo Fisher Scientific | Cat# 25742     |

**Oligonucleotides**

| Sequence       | Catalog Number |
|----------------|----------------|
| rat β-actin RV | GCAAATGCTTCTAGGCGGAC |
| rat β-actin RV | AAGAAAGGGGTAAAAACGCAGC |
| rat Nptn FW    | GCGCCAGAGAAACAAATTAAG |
| rat Nptn RV    | GCATGCTTTAGACGGTCATTG |
| rat Il-6 FW    | TAGTCCTTCCCTACCCAAACTTCC |
| rat Il-6 RV    | TTGGTCCCTAGCCACTCCTTC |
| rat Cxcl-1 FW  | CATTAATATTTAAGATGATGGATGC  |
| rat Cxcl-1 RV  | GCCTACCATCTTTAAGACTGCAAT |
| rat Bip FW     | TGGGTACATTGTCTGACTGGA |
|                      |          | Integrated DNA Technologies |                        |
|----------------------|----------|-----------------------------|------------------------|
| rat Bip RV           |          | CTCAAAGGTGACTTCAATCTGGG      |                        |
| rat Chop FW          |          | AGAGTGGTCAGTGCGCAGC          |                        |
| rat Chop RV          |          | CTCATTCTCCTGCTCCTTCTCC       |                        |
| rat Manf FW          |          | TGAGGTATCGAAGCCTCTGG         |                        |
| rat Manf RV          |          | AAGAAAGGGGTAAACGCAGC         |                        |
| mouse β-actin FW     |          | GCAAGTGCTTTCTAGGCAGC         |                        |
| mouse β-actin RV     |          | AAGAAAGGGGTAAACGCAGC         |                        |
| mouse II-6 FW        |          | CTCTGCAAGAGACTTCCATCCA       |                        |
| mouse II-6 RV        |          | AGTCTCCTCCTCCGGACTTGT        |                        |

### Software and Algorithms

| Software and Algorithms |          |                        |
|-------------------------|----------|------------------------|
| SPSS 22                 | IBM      | https://www.ibm.com/support/pages/spss-statistics-220-available-download |
| Flowjo X 10.0.7r2      | BD       | https://www.flowjo.com/solutions/flowjo                          |
| Image Lab              | BIO-RAD  | https://www.bio-rad.com/en-us/product/image-lab-software        |